BACKGROUND: Dectin-1 is the major receptor for fungal β-glucans on myeloid cells. We investigated whether defective Dectin-1 receptor function, because of the early stop codon polymorphism Y238X, enhances susceptibility to invasive aspergillosis (IA) in at-risk patients. METHODS: Association of Dectin-1 Y238X polymorphism with occurrence and clinical course of IA was evaluated in 71 patients who developed IA post hematopoietic stem cell transplantation (HSCT) and in another 21 non-HSCT patients with IA. The control group consisted of 108 patients who underwent HSCT. Functional studies were performed to investigate consequences of the Y238X Dectin-1 polymorphism. RESULTS: The Y238X allele frequency was higher in non-HSCT patients with IA (19.0% vs 6.9%-7.7%; P < .05). Heterozygosity for Y238X polymorphism in HSCT recipients showed a trend toward IA susceptibility (odds ratio, 1.79; 95% CI, .77-4.19; P = .17) but did not influence clinical course of IA. Functional assays revealed that although peripheral blood mononuclear cells with defective Dectin-1 function due to Y238X responded less efficiently to Aspergillus, corresponding macrophages showed adequate response to Aspergillus. CONCLUSIONS: Dectin-1 Y238X heterozygosity has a limited influence on susceptibility to IA and may be important in susceptible non-HSCT patients. This is partly attributable to redundancy inherent in the innate immune system. Larger studies are needed to confirm these findings.
BACKGROUND:Dectin-1 is the major receptor for fungal β-glucans on myeloid cells. We investigated whether defective Dectin-1 receptor function, because of the early stop codon polymorphism Y238X, enhances susceptibility to invasive aspergillosis (IA) in at-risk patients. METHODS: Association of Dectin-1 Y238X polymorphism with occurrence and clinical course of IA was evaluated in 71 patients who developed IA post hematopoietic stem cell transplantation (HSCT) and in another 21 non-HSCT patients with IA. The control group consisted of 108 patients who underwent HSCT. Functional studies were performed to investigate consequences of the Y238X Dectin-1 polymorphism. RESULTS: The Y238X allele frequency was higher in non-HSCT patients with IA (19.0% vs 6.9%-7.7%; P < .05). Heterozygosity for Y238X polymorphism in HSCT recipients showed a trend toward IA susceptibility (odds ratio, 1.79; 95% CI, .77-4.19; P = .17) but did not influence clinical course of IA. Functional assays revealed that although peripheral blood mononuclear cells with defective Dectin-1 function due to Y238X responded less efficiently to Aspergillus, corresponding macrophages showed adequate response to Aspergillus. CONCLUSIONS:Dectin-1 Y238X heterozygosity has a limited influence on susceptibility to IA and may be important in susceptible non-HSCT patients. This is partly attributable to redundancy inherent in the innate immune system. Larger studies are needed to confirm these findings.
Authors: W J F M van der Velden; N M A Blijlevens; F M H M Maas; N P M Schaap; J H Jansen; B A van der Reijden; T Feuth; H Dolstra; J P Donnelly Journal: Bone Marrow Transplant Date: 2009-02-16 Impact factor: 5.483
Authors: Theo S Plantinga; Walter J F M van der Velden; Bart Ferwerda; Annemiek B van Spriel; Gosse Adema; Ton Feuth; J Peter Donnelly; Gordon D Brown; Bart-Jan Kullberg; Nicole M A Blijlevens; Mihai G Netea Journal: Clin Infect Dis Date: 2009-09-01 Impact factor: 9.079
Authors: Bart Ferwerda; Gerben Ferwerda; Theo S Plantinga; Janet A Willment; Annemiek B van Spriel; Hanka Venselaar; Clara C Elbers; Melissa D Johnson; Alessandra Cambi; Cristal Huysamen; Liesbeth Jacobs; Trees Jansen; Karlijn Verheijen; Laury Masthoff; Servaas A Morré; Gert Vriend; David L Williams; John R Perfect; Leo A B Joosten; Cisca Wijmenga; Jos W M van der Meer; Gosse J Adema; Bart Jan Kullberg; Gordon D Brown; Mihai G Netea Journal: N Engl J Med Date: 2009-10-29 Impact factor: 91.245
Authors: Louis Y A Chai; Bart Jan Kullberg; Alieke G Vonk; Adilia Warris; Alessandra Cambi; Jean-Paul Latgé; Leo A B Joosten; Jos W M van der Meer; Mihai G Netea Journal: Infect Immun Date: 2009-02-09 Impact factor: 3.441
Authors: Pierre-Yves Bochud; Jason W Chien; Kieren A Marr; Wendy M Leisenring; Arlo Upton; Marta Janer; Stephanie D Rodrigues; Sarah Li; John A Hansen; Lue Ping Zhao; Alan Aderem; Michael Boeckh Journal: N Engl J Med Date: 2008-10-23 Impact factor: 91.245
Authors: D Neofytos; D Horn; E Anaissie; W Steinbach; A Olyaei; J Fishman; M Pfaller; C Chang; K Webster; K Marr Journal: Clin Infect Dis Date: 2009-02-01 Impact factor: 9.079
Authors: Daniel R Calabrese; Ping Wang; Tiffany Chong; Jonathan Hoover; Jonathan P Singer; Dara Torgerson; Steven R Hays; Jeffrey A Golden; Jasleen Kukreja; Daniel Dugger; Jason D Christie; John R Greenland Journal: JCI Insight Date: 2019-11-14
Authors: Michael K Mansour; Jenny M Tam; Nida S Khan; Michael Seward; Peter J Davids; Sravanthi Puranam; Anna Sokolovska; David B Sykes; Zeina Dagher; Christine Becker; Antoine Tanne; Jennifer L Reedy; Lynda M Stuart; Jatin M Vyas Journal: J Biol Chem Date: 2013-04-22 Impact factor: 5.157
Authors: A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl Journal: Stud Mycol Date: 2021-05-10 Impact factor: 16.097
Authors: Cynthia E Fisher; Tobias M Hohl; Wenhong Fan; Barry E Storer; David M Levine; Lu Ping Zhao; Paul J Martin; Edus H Warren; Michael Boeckh; John A Hansen Journal: Blood Date: 2017-03-07 Impact factor: 22.113
Authors: M Carmen Herrero-Sánchez; Eduardo B Angomás; Cristina de Ramón; Juan J Tellería; Luis A Corchete; Sara Alonso; M Del Carmen Ramos; María J Peñarrubia; Saioa Márquez; Nieves Fernández; Luis J García Frade; Mariano Sánchez Crespo Journal: Infect Immun Date: 2018-11-20 Impact factor: 3.441
Authors: Anupam Jhingran; Katrina B Mar; Debra K Kumasaka; Sue E Knoblaugh; Lisa Y Ngo; Brahm H Segal; Yoichiro Iwakura; Clifford A Lowell; Jessica A Hamerman; Xin Lin; Tobias M Hohl Journal: Cell Rep Date: 2012-11-29 Impact factor: 9.423